Daily Roundup

MVF.ASX VLS.ASX WDS.ASX MFG.ASX MAP.ASX

Monash IVF faces headwinds but gains market share

Monash IVF Group Limited has tempered expectations for FY26, guiding for underlying net profit after tax between $17 million and $18 million. The fertility treatment provider is grappling with a softer Australian assisted reproductive technology market, which has seen stimulated cycle volumes decline 4.7% as of April, with weakness persisting through May and June.

Despite the challenging backdrop, there's a silver lining. Monash has lifted its national market share to 20.1%, capturing ground in several states. International operations are also firing, and the company is rolling out new clinical appointments to expand its network. Management is pursuing operational and cost efficiency initiatives that should deliver more meaningful benefits in FY27.

Vita Life Sciences on track for solid half-year

Over in the wellness space, Vita Life Sciences is expecting H1 2026 sales between $46.3 million and $47.3 million, marking modest growth from $45.5 million in the prior corresponding period. Pre-tax profit is anticipated to land between $6.8 million and $7.3 million, broadly in line with last year's $6.8 million result.

The growth is being driven by established markets in Australia and Malaysia/Singapore, though this is partially offset by lower exports to China due to regulatory shifts and channel dynamics. The company maintains a fortress balance sheet with substantial cash reserves, no debt, and continued cash generation to fund strategic investments.

Woodside makes bold Browse move

Energy giant Woodside Energy has exercised its pre-emption right to acquire PetroChina's 10.67% stake in the Browse Joint Venture. The deal involves an upfront payment of US$225 million to CNPC, plus reimbursement of cash call contributions, along with a contingent payment of US$175 million if the joint venture reaches a final investment decision by mid-2032.

The Browse resource represents Australia's largest undeveloped conventional gas field, with potential to produce 11.4 million tonnes per annum of liquefied natural gas, liquefied petroleum gas, and domestic gas. CEO Liz Westcott framed the acquisition as a disciplined, capital-efficient way to unlock long-term cash flow potential from these high-quality assets.

Magellan gets green light for Barrenjoey merger

The Australian Competition and Consumer Commission has given the thumbs up to Magellan Financial Group's merger with Barrenjoey Capital Partners, clearing the way for completion in early July. Pending shareholder approval at the October annual general meeting, the combined entity will rebrand as Barrenjoey Group Limited, with the ASX ticker shifting from MFG to BJY. The investment distribution brand will also transition to Barrenjoey Investment Partners.

Microba bounces back with $5M raise and breakeven roadmap

Microba Life Sciences has returned to trading after announcing a $5 million capital raise at $0.05 per share, backed by existing investors and newcomers including major shareholder Sonic Healthcare, which committed $1.5 million. The biotech company is charting a course to cashflow break-even by the end of 2027, underpinned by streamlined operations and artificial intelligence enhancements.

The momentum is already evident. Microba has notched 11 consecutive quarters of core testing sales growth, with revenues up 106% over the past year, fueled by enterprise-style healthcare contracts. A category-defining testing product is slated to launch in Q3 this year, expected to catalyze further adoption. The therapeutics division is also actively pursuing partnerships with support from a Boston-based advisor, following encouraging clinical trial results. Eligible shareholders can apply for up to $30,000 of new shares under a Share Purchase Plan at the same offer price.